低危或中危前列腺癌患者立体定向体部放疗1期剂量递增研究的长期结局
该单中心1期剂量递增研究纳入2009至2012年136例低危或中危前列腺癌患者,SBRT剂量从32.5 Gy/5次递增至40 Gy/5次。中位随访7.3至10.5年,8年PSA失败累积发生率32.5 Gy组26%、35 Gy组15%、37.5 Gy组3.4%、40 Gy组6.6%;较高剂量(37.5-40 Gy)与较好PSA复发率相关(p=0.011),无4级事件,较高剂量未增加晚期≥2级GI(p=0.2)或GU(p>0.9)毒性。
要点
- 8年PSA失败累积发生率:32.5 Gy组26%、35 Gy组15%、37.5 Gy组3.4%、40 Gy组6.6%。
- 较高剂量(37.5-40 Gy)与较好PSA复发率相关(p=0.011),有利中危 vs 不利中危亦相关(p=0.002)。
- 8年无晚期≥2级毒性生存率:GI 94%、GU 86%;无4级事件。
核心结论
- SBRT剂量32.5至40 Gy与中重度毒性低发生率相关,较高剂量在治疗后8年带来更优疾病控制结局。
研究设计与样本
- 单中心1期剂量递增研究,2009至2012年纳入并治疗136例低危或中危前列腺癌患者。
- 初始剂量水平为32.5 Gy/5次,随后序贯递增至35 Gy、37.5 Gy和40 Gy,均分5次隔日照射。
- 主要终点为晚期治疗相关毒性,次要终点包括前列腺特异性抗原(PSA)失败。
主要发现
- 中位随访:32.5 Gy组10.5年、35 Gy组9.9年、37.5 Gy组8.2年、40 Gy组7.3年。
- 8年PSA失败累积发生率:32.5 Gy组26%、35 Gy组15%、37.5 Gy组3.4%、40 Gy组6.6%。
- 较高放疗剂量(37.5-40 Gy)与较好PSA复发率相关(p=0.011),有利中危(对比不利中危)亦与较好PSA复发率相关(p=0.002)。
- 8年无晚期≥2级毒性生存率:GI毒性94%、GU毒性86%;无4级事件记录。
- 较高剂量水平与晚期≥2级GI毒性(p=0.2)或GU毒性(p>0.9)发生率升高无关。
临床怎么用
- 原文结论指出SBRT剂量32.5至40 Gy与中重度毒性低发生率相关,较高剂量在治疗后8年带来更优疾病控制结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ultrahypofractionated stereotactic body radiation therapy (SBRT) has become a standard treatment intervention for localized prostate cancer. OBJECTIVE: To report final long-term tumor control outcomes and late gastrointestinal (GI) and genitourinary (GU) toxicities from a single-center phase 1 dose escalation study using SBRT for patients with low- or intermediate-risk prostate cancer. DESIGN, SETTING AND PARTICIPANTS: Between 2009 and 2012, 136 patients were enrolled and treated. The initial dose level was 32.5 Gy in five fractions. Doses were then sequentially escalated to 35 Gy, 37.5 Gy, and 40 Gy in five fractions delivered every other day. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was late treatment-related toxicity. Secondary endpoints included prostate-specific antigen (PSA) failure. RESULTS AND LIMITATIONS: The median follow-up was 10.5 yr for the 32.5-Gy group, 9.9 yr for the 35-Gy group, 8.2 yr for the 37.5-Gy group, and 7.3 yr for the 40-Gy group. The 8-yr cumulative incidence of PSA failure was 26% for 32.5 Gy, 15% for 35 Gy, 3.4% for 37.5 Gy, and 6.6% for 40 Gy. Higher radiation dose (37.5-40 Gy) and favorable intermediate risk (vs unfavorable intermediate risk) were associated with better PSA recurrence rates (p = 0.011 and 0.002, respectively). The 8-yr actuarial probability rates for survival free from late grade ≥2 toxicity were 94% for GI toxicity and 86% for GU toxicity. No grade 4 events were recorded. Higher dose levels were not associated with higher rates of late grade ≥2 GI (p = 0.2) or GU (p > 0.9) toxicity. CONCLUSIONS: SBRT doses ranging from 32.5 to 40 Gy were associated with low incidence of moderate or severe toxicities. Higher doses resulted in superior disease control outcomes 8 yr after treatment. PATIENT SUMMARY: We investigated the association between the radiotherapy dose used and the rate of control of prostate cancer. We found that higher doses resulted in more favorable outcomes without excess toxicity. This trial is registered on ClinicalTrials.gov as NCT00911118.
引用
- Moore A, Kollmeier MA, McBride SM, et al. Long-term Outcomes from a Phase 1 Dose Escalation Study Using Stereotactic Body Radiotherapy for Patients with Low- or Intermediate-risk Prostate Cancer. Eur Urol Oncol. 2023. PMID: 37949730. doi:10.1016/j.euo.2023.10.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。